1056149-69-9

Basic information

• Product Name: (2E)-(N,N-dimethylamino)-2-butenoyl chloride
• Synonyms: (2E)-(N,N-dimethylamino)-2-butenoyl chloride
• CAS NO: 1056149-69-9
• Molecular Weight: 147.605
• Mol File: 1056149-69-9.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: (2E)-(N,N-dimethylamino)-2-butenoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-(N,N-dimethylamino)-2-butenoyl chloride(1056149-69-9)
• EPA Substance Registry System: (2E)-(N,N-dimethylamino)-2-butenoyl chloride(1056149-69-9)

Safety Data

• Hazardous Substances Data: 1056149-69-9(Hazardous Substances Data)

Usage

General Description

(2E)-(N,N-dimethylamino)-2-butenoyl chloride, also known as DMBA-Cl, is a chemical compound with the molecular formula C8H14ClNO. It is a clear, colorless liquid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. DMBA-Cl is known to be a strong acylating agent and is often utilized in the production of amides, esters, and other organic compounds. It is a highly reactive compound and should be handled with care due to its potential to cause skin and respiratory irritation upon contact or inhalation. Additionally, DMBA-Cl is considered to be a hazardous material and should be stored and handled in accordance with appropriate safety measures to prevent accidents and exposure.

Upstream product

• 79-37-8 oxalyl dichloride 
• 149586-32-3 (2E)-4-(dimethylamino)but-2-enoic acid 
• 1130155-48-4 (E)-4-(dimethylamino)-2-butenoic acid hydrochloride 

Downstream Products

• 257933-82-7 pelitinib 
• 848133-88-0 4-chloro-6-(5-(dimethylamino)-2-oxopent-3-enyl)-7-ethoxyquinoline-3-carbonitrile 
• 544417-30-3 (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-buteneamide 
• 848134-35-0 C₃₃H₃₉ClN₆O₆ 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting EGFR

This letter describes the construction of conformationally constrained quinazoline analogues. Structure-activity relationship studies led to the identification of the lead compound 9n. Compound 9n exhibits effective in vitro activity against A431WT,overexpression and H1975 [L858R/T790M] cancer cell lines but is significantly less effective against EGFR negative cancer cell lines (SW620, A549, and K562). Compound 9n was also assessed for potency in enzymatic assays and in vivo antitumor studies. The results indicated that 9n is a potent kinase inhibitor against both wild-type and T790M mutant EGFR kinase. Meanwhile, an oral administration of 9n at a dose of 200 mg/kg produced a considerable antitumor effect in a A431 xenograft model, as compared to gefitinib. A preliminary pharmacokinetic study of 9n also indicates it has good pharmacokinetic properties, and therefore, it is a good starting point for further development.

Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new class of covalent pan-PI5P4K inhibitors with potent biochemical and cellular activity. Our designs are based on THZ-P1-2, a covalent PI5P4K inhibitor previously developed in our lab. Here, we report further structure-guided optimization and structure-activity relationship (SAR) study of this scaffold, resulting in compound 30, which retained biochemical and cellular potency, while demonstrating a significantly improved selectivity profile. Furthermore, we confirm that the inhibitors show efficient binding affinity in the context of HEK 293T cells using isothermal CETSA methods. Taken together, compound 30 represents a highly selective pan-PI5P4K covalent lead molecule.

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

Quinazoline derivative, preparation method and pharmaceutical application thereof

The invention discloses a quinazoline derivative, a preparation method and pharmaceutical application thereof. The invention provides the quinazoline derivative which is a compound shown as formula Iin the specification, and also provides a pharmaceutical